Allosteric modulation of G-protein-coupled receptors

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 12, 2001, Pages 1889-1904

  Soudijn, W ^a   Van Wijhngaarden, I ^a   Ijzerman, A P ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Allosteric modulators; G protein coupled receptors; Negative co operativity; Positive co operativity

Indexed keywords

2 CHLORO 6 [3 [1,1 DIMETHYL 2 (2 NAPHTHYL)ETHYLAMINO] 2 HYDROXYPROPOXY]BENZONITRILE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 7 HYDROXYIMINOCYCLOPROPAN[B]CHROMEN 1A CARBOXYLIC ACID ETHYLESTER; ADENOSINE RECEPTOR; AGMATINE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR; AMILORIDE DERIVATIVE; BETA ADRENERGIC RECEPTOR; BRUCINE; CALCIUM ANTAGONIST; CALCIUM ION; CHOLINERGIC RECEPTOR; DOPAMINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; K 5720; LEUCYLSERYLALANYLLEUCINE; METABOTROPIC RECEPTOR; MUSCARINIC RECEPTOR; N (2,3 DIPHENYL 1,2,4 THIADIAZOL 5(2H) YLIDENE)METHANAMINE; N [2 HYDROXY 3 (3 CHLORO 2 CYANOPHENOXY)PROPYL] 1,1 DIMETHYL 2 (2 NAPTHYL)ETHYLAMINE; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; OLEAMIDE; OPIATE RECEPTOR; PROLYLLEUCYLGLYCINAMIDE; SEROTONIN RECEPTOR; STAUROSPORINE DERIVATIVE; THIADIAZOLE DERIVATIVE; TRIPEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; DRUG CONCENTRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; FUTUROLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; NONHUMAN; PROTEIN INTERACTION; PUBLICATION; RAT; REVIEW; SCREENING;

EID: 0035211686     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.12.1889     Document Type: Review

References (64)

1. Allosteric proteins and cellular control systems
2. Drug discovery: A historical perspective
3. Structural basis of G protein-coupled receptor function
4. Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: Radioligand binding studies
5. SCH-202676: An allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors
6. Subtype-selective positive cooperative interactions between brucine analogs and acetylcholine at muscarinic receptors: Functional studies
7. Allosteric interaction of staurosporine and other indolocarbazoles with N-[methyl-3H] scopolamine and acetylcholine at muscarinic receptor subtypes: Identification of a second allosteric site
8. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors
9. 3H]ligand for the common allosteric site of muscarinic acetylcholine M2 receptors
10. 2-receptor allosterically
11. Probing the size of a hydrophobic binding pocket within the allosteric site of muscarinic acetylcholine M2-receptors: Unilateral variation of alkane bisammonium-type ligands
12. 2-adrenoceptors
13. 1-adrenoceptor subtypes
14. 1A-adrenergic receptor
15. 1-adrenergic receptor function by benzodiazepines: A potential site of allosteric modulation
16. 2-adrenergic receptors
17. 2A-adrenergic receptor
18. 2A adrenoceptor: Allosteric modulation by amilorides
19. 2-adrenoceptor: Competitive antagonism and allosteric activation
20. Isolation and characterization of an endogenous peptide from rat brain interacting specifically with the serotonergic 1B receptor subtypes
21. 5-Hydroxytryptamine-moduline, a new endogenous cerebral peptide controls the serotonergic activity via its interaction with 5-hydroxytryptamine 1B/1D receptors
22. Specific interaction with of 5-HT-moduline with human 5-HT1B as well as 5-HT1D receptors expressed in transfected cultured cells
23. Immunocytochemical localization of neurons expressing 5-HT-moduline in mouse brain
24. Endoproteolytic activity in mammalian brain membranes cleaves 5-hydroxytryptamine - Moduline into dipeptides
25. Acute stress induces a differential increase of 5-HT moduline (LSAL) tissue content in various rat brain areas
26. 5-Hydroxytryptamine-moduline: A novel endogenous peptide involved in the control of anxiety
27. The possible role of 5-HT1B/D receptors in psychiatric disorders and their potential as a target for therapy
28. 5-HT-moduline controls serotonergic activity: Implication in neuroimmune reciprocal regulation mechanisms
29. Brain lipids that induce sleep are novel modulators of 5-hydroxytryptamine receptors
30. 1A serotonin receptor potentiation by the biological active lipid oleamide
31. Oleamide-induced modulation of 5-hydroxytryptamine receptor mediated signalling
32. 7 receptors
33. 4 dopamine receptors by amiloride and amiloride analogues
34. 4 dopamine receptor is coupled to three distinct sites of allosteric modulation
35. Design, synthesis and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide
36. Synthesis and dopamine modulation activity of unsubstituted and substituted triproline analogues of L-prolyl-L-leucylglycinamide (PLG)
37. Receptors for purines and pyrimidines
38. Allosteric enhancement of adenosine receptors
39. 1 receptor binding and function by 2-amino-3-benzoylthiophenes
40. 1 adenosine receptor, lowers the threshold for ischemic preconditioning in dogs
41. 1 receptor binding by 2-amino-3-benzoylthiophenes
42. 1 receptor allosteric enhancer PD 81,723 on agonist binding to brain and adipocyte membranes
43. Allosteric enhancer PD 81,723 acts by novel mechanism to potentiate cardiac actions of adenosine
44. Functional activity of the adenosine binding enhancer, PD 81,723, in the in vitro hippocampal slice
45. 1 receptor
46. Characterization of glutamate, aspartate and GABA release from ischemic rat cerebral cortex
47. Novel approach for enhancing atrioventricular nodal conduction delay mediated by endogenous adenosine
48. 1 receptor - Dependent and - Independent effects of the allosteric enhancer PD 81,723
49. 1 adenosine receptors
50. 1 adenosine receptor coupling to G proteins
51. 1 receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding
52. 2A receptors by amiloride analogues and sodium ions
53. 2A receptor antagonist HW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP
54. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding
55. 2-methyl-6-(phenylethynyl)-pyridine (MPEP) a potent selective and systemically active mglu 5 receptor antagonist
56. The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan [b] chromen-1α-carboxylic acid ethylester interact with overlapping binding pockets in the transmembrane region of glutamate receptors
57. Novel allosteric antagonists shed light on mglu 5 receptors and CNS disorders
58. The calcium receptor and calcimimetics
59. 2+-sensing receptor
60. Calcimimetics with potent and selective activity on parathyroid calcium receptor
61. NPS R-568: A typeII calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium
62. 2+ receptors in rats
63. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats
64. 2+-sensing receptor